PMID- 35123846
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20220929
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Linking)
VI  - 121
IP  - 10
DP  - 2022 Oct
TI  - Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective 
      chart review study of real-world use in a tertiary hospital in Taiwan.
PG  - 1929-1937
LID - S0929-6646(22)00040-7 [pii]
LID - 10.1016/j.jfma.2022.01.020 [doi]
AB  - BACKGROUND: Radium-223 is an alpha-emitting, bone-targeting radiopharmaceutical 
      that confers a survival benefit in patients with confirmed bone-metastatic, 
      castration-resistant prostate cancer with no visceral metastases. We studied 
      real-world use of radium-223 in eligible patients from a tertiary hospital. 
      METHODS: We retrospectively collected clinical data of patients treated with 
      radium-223 in Tungs' Taichung MetroHarbor Hospital by chart review. Data included 
      biochemical parameters, pain scores, other prostate cancer treatments received 
      and adverse events (AEs). RESULTS: Of 36 patients included in the study, 12 
      patients received radium-223 as first-line therapy, 11 as second-line treatment 
      and 13 as third-line treatment. Prostate-specific antigen significantly increased 
      from baseline in patients who received radium-223 as third-line treatment and in 
      patients who received radium-223 post-chemotherapy. Pain scores significantly 
      decreased when radium-223 was given as second-line and as third-line treatment. 
      In the patients who were naive to novel anti-hormone (NAH) therapy and 
      chemotherapy, mean alkaline phosphatase level significantly decreased from 
      baseline. The most common AE was anemia, found in 16.7% of patients. CONCLUSION: 
      Radium-223 had early biochemical benefits, while in the later stages of the 
      disease, it reduced bone pain in this real-world cohort of chemotherapy-naive, 
      NAH-naive patients, and patients with prior therapy, from a tertiary institution 
      in Taiwan.
CI  - Copyright (c) 2022 Formosan Medical Association. Published by Elsevier B.V. All 
      rights reserved.
FAU - Weng, Wei-Chun
AU  - Weng WC
AD  - Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, 
      Taichung, Taiwan; Department of Nursing, Jen-Teh Junior College of Medicine, 
      Nursing and Management, Miaoli, Taiwan; Division of Nuclear Medicine, Tungs' 
      Taichung MetroHarbor Hospital, Taichung, Taiwan.
FAU - Huang, Li-Hua
AU  - Huang LH
AD  - Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, 
      Taichung, Taiwan.
FAU - Tseng, Neng-Chuan
AU  - Tseng NC
AD  - Division of Nuclear Medicine, Tungs' Taichung MetroHarbor Hospital, Taichung, 
      Taiwan.
FAU - Ou, Yen-Chuan
AU  - Ou YC
AD  - Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, 
      Taichung, Taiwan. Electronic address: ycou228@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220203
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - 0 (Radioisotopes)
RN  - 0 (Radiopharmaceuticals)
RN  - 8BR2SOL3L1 (Radium-223)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - W90AYD6R3Q (Radium)
SB  - IM
MH  - Alkaline Phosphatase
MH  - *Bone Neoplasms/radiotherapy
MH  - Humans
MH  - Male
MH  - Pain/drug therapy
MH  - Prostate-Specific Antigen
MH  - *Prostatic Neoplasms, Castration-Resistant/drug therapy/radiotherapy
MH  - Radioisotopes/therapeutic use
MH  - Radiopharmaceuticals/therapeutic use
MH  - *Radium/therapeutic use
MH  - Retrospective Studies
MH  - Taiwan
MH  - Tertiary Care Centers
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bone metastasis
OT  - Castration-resistant prostate cancer (CRPC)
OT  - Prostate cancer
OT  - Radium-223
OT  - Symptomatic metastatic CRPC
COIS- Declaration of competing interest The authors have no conflicts of interest 
      relevant to this article.
EDAT- 2022/02/07 06:00
MHDA- 2022/09/21 06:00
CRDT- 2022/02/06 20:29
PHST- 2021/07/12 00:00 [received]
PHST- 2021/11/19 00:00 [revised]
PHST- 2022/01/17 00:00 [accepted]
PHST- 2022/02/07 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/02/06 20:29 [entrez]
AID - S0929-6646(22)00040-7 [pii]
AID - 10.1016/j.jfma.2022.01.020 [doi]
PST - ppublish
SO  - J Formos Med Assoc. 2022 Oct;121(10):1929-1937. doi: 10.1016/j.jfma.2022.01.020. 
      Epub 2022 Feb 3.